ISG15 and liver cancer: More significantly, sorafenib non-responsive HCC patients demonstrated a notably higher expression of ISG15 in comparison to the responders (Fig. 5E), and this elevated ISG15 expression is indicative of an unfavorable prognosis among liver cancer patients (Fig. 5F).